文献速递创伤与烧伤复苏、休克与脓毒症

急诊科床旁黏弹性止血检测对创伤患者的效用

Utility of point of care viscoelastic haemostatic assays for trauma patients in the emergency department.
PubMed 文献 · Scand J Trauma Resusc Emerg Med · 2025-04-24
一句话结论在澳大利亚急诊科创伤患者中,早期床旁黏弹性止血检测(VHA)单独预测24小时大量输血准确性不足,但与MHP决策评分联合可能提高排除效能。

这项前瞻性观察研究在澳大利亚急诊科连续纳入114例创伤患者,于分诊后1小时内使用TEG6s™进行床旁黏弹性止血检测(VHA),主要终点为预测24小时大量输血(MT)的准确性。结果显示,任何异常VHA结果预测MT的敏感性为73.6%(95%CI 59.7-84.7),特异性为49.3%(95%CI 36.1-62.3);枸橼酸化功能性纤维蛋白原(CFF)组分对MT的「纳入」特异性较高,为86.9%。VHA与已验证的MHP决策评分联合时效能提高,例如VHA正常且创伤相关严重出血评分(Trauma Associated Severe Haemorrhage score)<8.5时,排除MT需求的敏感性达96.2%。作者认为,早期VHA单独检测不足以可靠预测大量输血需求。

要点

  • 急诊创伤患者中,任何异常VHA结果预测24小时大量输血的敏感性为73.6%(95%CI 59.7-84.7),特异性为49.3%(95%CI 36.1-62.3)。
  • TEG6s™的枸橼酸化功能性纤维蛋白原(CFF)组分对MT「纳入」特异性较高,达86.9%。
  • VHA与已验证的MHP决策评分联合可提高效能:VHA正常且Trauma Associated Severe Haemorrhage评分<8.5时,排除MT需求的敏感性为96.2%。
  • 本队列114例中,住院死亡率为7.0%,91.2%接受了输血。
  • 作者结论:急诊科早期VHA单独检测不足以可靠预测大量输血需求。

适用人群与场景

  • 澳大利亚急诊科连续创伤患者,分诊后1小时内纳入,为期三年的研究窗口。

研究设计与关键结果

  • 前瞻性观察研究,纳入114例创伤患者,采用STARD指南报告,床旁设备为TEG6s™(Haemonetics, Braintree, MA, USA)。
  • 按VHA结果分为VHA正常组(n=44)与VHA异常组(n=70)。
  • 主要终点:VHA预测24小时大量输血(MT)的准确性;任何异常VHA结果的敏感性为73.6%(95%CI 59.7-84.7),特异性为49.3%(95%CI 36.1-62.3)。
  • CFF组分对MT「纳入」特异性为86.9%。
  • VHA与已验证的MHP决策评分联合时效能提高;VHA正常且Trauma Associated Severe Haemorrhage评分<8.5时,排除MT需求的敏感性为96.2%。
  • 住院死亡率为7.0%,91.2%的患者接受了输血。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:作者指出需进一步研究VHA检测参数能否加入或替代现有临床评分中的INR,以用于急诊输血决策;原文未报告其他局限性。

对床旁实践的改变

  • 作者认为,急诊科早期VHA单独检测不足以可靠预测大量输血需求;VHA与已验证的MHP决策评分联合可能提高效能,例如VHA正常且Trauma Associated Severe Haemorrhage评分<8.5时对排除MT需求的敏感性为96.2%。
  • 作者建议进一步研究VHA检测参数能否加入或替代现有临床评分中的INR,以用于急诊患者的输血决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVES: Traumatic haemorrhage often requires initiation of a massive haemorrhage protocol (MHP). The primary aim of this exploratory Emergency Department (ED) study was to examine the utility of point of care Viscoelastic Haemostatic Assays (VHA) in terms of accuracy. The primary outcome was prediction of the need for massive transfusion (MT) at 24-hours.

METHODS: Prospective observational study of consecutive trauma patients investigated with reported using STARD guidelines. Patients in an Australian ED setting < 1-hour from triage enrolled in a three-year window. The point-of-care device used was a TEG6s™ (Haemonetics, Braintree, MA, USA). The primary outcome was accuracy VHA testing for predicting MT delivery at 24-hours (an internationally recognised of massive transfusion was used). Other trauma outcomes such as product transfusion, injury severity score (ISS) and demographics were recorded. For analysis of accuracy the cohort was divided into VHA-normal (n = 44) and VHA-abnormal (n = 70) binary groups. Secondary outcomes included utility of TEG6s™ individual components and accuracy of VHA when combined with validated MHP decision scores.

RESULTS: Among eligible cases (n = 114) in-patient mortality was 7.0% with 91.2% receiving transfusion. Presence of (any) abnormal VHA result provided a 73.6% (95%CI 59.7-84.7) sensitivity and 49.3% (95%CI 36.1-62.3) specificity for predicting MT. Citrated Functional Fibrinogen (CFF) component had a higher performance for MT "rule-in" specificity (86.9%). When VHA was combined with validated MHP decision scores performance was increased. For example, normal VHA with Trauma Associated Severe Haemorrhage score < 8.5 was observed to yield a sensitivity of 96.2% for MT requirement rule-out. Further studies should examine if VHA test parameters can be added or (replace INR) in the existing clinical scores used to make decisions about transfusion in ED patients.

CONCLUSION: The standalone performance of early VHA testing in the ED setting was insufficient to reliably for predict a need for massive transfusion.

来源:Scand J Trauma Resusc Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Coggins AR, Nguyen VDD, Pasalic L, et al. Utility of point of care viscoelastic haemostatic assays for trauma patients in the emergency department. Scand J Trauma Resusc Emerg Med. 2025. PMID: 40275305. doi:10.1186/s13049-025-01388-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。